News | February 16, 2024
Marksans Q3 FY24 revenue up 22% at Rs 586 Cr
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
Gross profit was Rs. 313.3 crore, up by +30.4% YoY with a Gross margin of 53.5%
The company is committed to a new category development in areas like adult Immunization with products like Shingrix to make a positive impact to the lives of the patients in India
These re-agent and diagnostic test kits come with 99.7% accuracy
Anticipates approx. US$8 billion in revenues for Comirnaty and Paxlovid
General Medicine grows 5% and Vaccines 10% led by Shingrix
Revenue in the three months ended on Oct. 1 also slipped by 42% to US$ 13.23 billion
Profit after tax (before exceptional items) up 23% to Rs 215 crores
Low-leveraged balance sheets, sizeable liquidity to keep credit profiles stable
API, PFI, and Finished dosages contribute 30%, 15%, and 55% of revenue from operations respectively for Q1FY24
Acquisition of biologics manufacturing facility in Bangalore to complete by the end of the third quarter in FY 24
Subscribe To Our Newsletter & Stay Updated
